BlackRock Inc. grew its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) by 199.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 588,308 shares of the company’s stock after purchasing an additional 392,151 shares during the period. BlackRock Inc. owned about 1.45% of Galectin Therapeutics worth $3,742,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. First Allied Advisory Services Inc. purchased a new position in shares of Galectin Therapeutics during the second quarter valued at $223,000. Belpointe Asset Management LLC purchased a new position in shares of Galectin Therapeutics during the second quarter valued at $277,000. Millennium Management LLC purchased a new position in shares of Galectin Therapeutics during the first quarter valued at $454,000. Finally, LPL Financial LLC purchased a new position in shares of Galectin Therapeutics during the first quarter valued at $112,000. Institutional investors and hedge funds own 13.85% of the company’s stock.

GALT opened at $4.78 on Friday. Galectin Therapeutics Inc. has a 1 year low of $1.28 and a 1 year high of $9.49. The stock has a market capitalization of $204.98 million, a price-to-earnings ratio of -9.76 and a beta of 2.76.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts expect that Galectin Therapeutics Inc. will post -0.44 EPS for the current fiscal year.

Several equities analysts have recently commented on GALT shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Galectin Therapeutics in a research note on Thursday, August 16th. BidaskClub upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Finally, ValuEngine upgraded Galectin Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $7.58.

In other Galectin Therapeutics news, Director Marc Rubin sold 11,900 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $6.58, for a total value of $78,302.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert S. Omenn sold 19,370 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $6.02, for a total value of $116,607.40. Following the completion of the sale, the director now directly owns 56,561 shares of the company’s stock, valued at approximately $340,497.22. The disclosure for this sale can be found here. In the last three months, insiders sold 100,370 shares of company stock valued at $614,487. Corporate insiders own 38.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Galectin Therapeutics Inc. (GALT) Holdings Increased by BlackRock Inc.” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://theolympiareport.com/2018/11/11/galectin-therapeutics-inc-galt-holdings-increased-by-blackrock-inc.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Recommended Story: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding GALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galectin Therapeutics Inc. (NASDAQ:GALT).

Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.